Prosecution Insights
Last updated: August 06, 2026
Application No. 18/548,119

NOVEL PROCESS FOR THE PREPARATION OF 2,5-DICHLORO-3-(5-(3,4-DIHYDROXY-5-NITROPHENYL)-1,2,4-OXADIAZOL-3-YL)-4,6-DIMETHYLPYRIDINE-1-OXIDE

Final Rejection §112
Filed
Aug 28, 2023
Priority
Feb 26, 2021 — IN 202141008206 +1 more
Examiner
HEASLEY, MEGHAN CHRISTINE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Msn Laboratories Private Limited R&D Center
OA Round
2 (Final)
77%
Grant Probability
Favorable
3-4
OA Rounds
1m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
98 granted / 127 resolved
+17.2% vs TC avg
Strong +34% interview lift
Without
With
+33.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
67 currently pending
Career history
164
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
33.1%
-6.9% vs TC avg
§102
19.9%
-20.1% vs TC avg
§112
28.9%
-11.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 127 resolved cases

Office Action

§112
Detailed Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-8, 10, 12, and 21 are pending. Claims 1-7 and 21 are allowed. Claims 8 and 10 are objected to. Claim 12 is rejected. Note from Examiner Examiner tried calling agent Parithosh Tungaturthi on 6/23/2026 for an Examiner’s Amendment but could not get in contact. Election/Restrictions Claim 1 is allowable. Claims 8, 10 and 12, previously withdrawn from consideration as a result of a restriction requirement, include all the limitations of an allowable claim. Pursuant to the procedures set forth in MPEP § 821.04(a), the restriction requirement between inventions, as set forth in the Office action mailed on 11/21/2025, is hereby withdrawn and claims 8, 10 and 12 are hereby rejoined and fully examined for patentability under 37 CFR 1.104. In view of the withdrawal of the restriction requirement, applicant(s) are advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Response to Amendments/Arguments Applicant’s 5/25/2026 amendments have overcome all previous objections and rejections (particularly the requirement of two instead of one of the steps of instant claim 1). Therefore, Applicant remarks from 5/25/2026 will not be addressed. However, in light of the rejoinder above, novel objections and rejections are necessitated and described below. Claim Objections Claim 8 is objected to because of the following informalities: The claim should begin with an “A”. Appropriate correction is required. Claim 10 is additionally objected to for depending from claim 8 and failing to remedy its deficiencies. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 12 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 12 is indefinite because it is unclear if it is a method or product claim. If it is a method claim, there are no concrete steps of the process. Additionally, “formula (I)” in line 2 does not have antecedent basis. Examiner recommends inserting appropriate steps if Applicant intended for this claim to be a method/process claim. Examiner additionally recommends inserting the structure of formula (I) into claim 12. Closest Prior Art The closest prior art to claims 8, 10 and 12 is Sathe et al. (WO2019123066). Sathe teaches the following process on the bottom of p. 3: PNG media_image1.png 232 598 media_image1.png Greyscale (particularly the last two steps of the prior art shown supra), wherein P of Formula (VI) is methyl. The prior art does not include instant formula (V) in the process. Therefore, the prior art does not provide motivation for, nor render obvious, the instant claims. It should be noted that claim 12 is rejected under 112(b) supra for being indefinite and not including process steps. Allowable Subject Matter Claims 1-7 and 21 are allowed. Conclusion Applicant’s amendments necessitated the new ground(s) of rejection presented in this Office Action. Accordingly, THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEGHAN C HEASLEY whose telephone number is (571)270-0785. The examiner can normally be reached Monday - Friday 8:30-4:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy Clark can be reached on 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MEGHAN C HEASLEY/Examiner, Art Unit 1626 /KAMAL A SAEED/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Aug 28, 2023
Application Filed
Feb 25, 2026
Non-Final Rejection mailed — §112
May 25, 2026
Response Filed
Jul 01, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12692263
SOS1 INHIBITORS AND USES THEREOF
3y 1m to grant Granted Jul 28, 2026
Patent 12692223
PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS
2y 6m to grant Granted Jul 28, 2026
Patent 12685726
Sulfoximines as inhibitors of NaV1.8
2y 7m to grant Granted Jul 21, 2026
Patent 12678428
A SYNERGISTIC COMPOSITION FOR INHIBITING VASCULAR CALCIFICATION
2y 7m to grant Granted Jul 14, 2026
Patent 12655145
P2X3 MODULATORS
3y 10m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+33.6%)
3y 1m (~1m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 127 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month